Abstract
Restenosis after angioplasty is caused usually by neointima formation characterized by aberrant vascular smooth muscle cell (VSMC) dedifferentiation. Myeloid-derived growth factor (MYDGF), secreted from bone marrow-derived monocytes and macrophages, has been found to have cardioprotective effects. In this study we investigated the effect of MYDGF to postinjury neointimal formation and the underlying mechanisms. Rat carotid arteries balloon-injured model was established. We found that plasma MYDGF content and the level of MYDGF in injured arteries were significantly decreased after balloon injury. Local application of exogenous MYDGF (50 μg/mL) around the injured vessel during balloon injury markedly ameliorated the development of neointimal formation evidenced by relieving the narrow endovascular diameter, improving hemodynamics, and reducing collagen deposition. In addition, local application of MYDGF inhibited VSMC dedifferentiation, which was proved by reversing the elevated levels of osteopontin (OPN) protein and decreased levels of α-smooth muscle actin (α-SMA) in the left carotid arteries. We showed that PDGF-BB (30 ng/mL) stimulated VSMC proliferation, migration and dedifferentiation in vitro; pretreatment with MYDGF (50−200 ng/mL) concentration-dependently eliminated PDGF-BB-induced cell proliferation, migration and dedifferentiation. Molecular docking revealed that MYDGF had the potential to bind with sphingosine-1-phosphate receptor 2 (S1PR2), which was confirmed by SPR assay and Co-IP analysis. Pretreatment with CCG-1423 (Rho signaling inhibitor), JTE-013 (S1PR2 antagonist) or Ripasudil (ROCK inhibitor) circumvented the inhibitory effects of MYDGF on VSMC phenotypic switching through inhibiting S1PR2 or its downstream RhoA-actin monomers (G-actin) /actin filaments (F-actin)-MRTF-A signaling. In summary, this study proves that MYDGF relieves neointimal formation of carotid arteries in response to balloon injury in rats, and suppresses VSMC dedifferentiation induced by PDGF-BB via S1PR2-RhoA-G/F-actin-MRTF-A signaling pathway. In addition, our results provide evidence for cross talk between bone marrow and vasculature.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Moussa ID, Mohananey D, Saucedo J, Stone GW, Yeh RW, Kennedy KF, et al. Trends and outcomes of restenosis after coronary stent implantation in the United States. J Am Coll Cardiol. 2020;76:1521–31.
Yang X, Yang Y, Guo J, Meng Y, Li M, Yang P, et al. Targeting the epigenome in in-stent restenosis: from mechanisms to therapy. Mol Ther Nucleic Acids. 2021;23:1136–60.
Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol. 2020;75:2664–78.
Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, et al. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80:348–72.
Zeng Z, Xia L, Fan S, Zheng J, Qin J, Fan X, et al. Circular RNA CircMAP3K5 acts as a microRNA-22-3p sponge to promote resolution of intimal hyperplasia via TET2-mediated smooth muscle cell differentiation. Circulation. 2021;143:354–71.
Melnik T, Jordan O, Corpataux J-M, Delie F, Saucy F. Pharmacological prevention of intimal hyperplasia: a state-of-the-art review. Pharmacol Ther. 2022;235:108157.
Liu M, Gomez D. Smooth muscle cell phenotypic diversity. Arterioscler Thromb Vasc Biol. 2019;39:1715–23.
Ashraf JV, Al Haj Zen A. Role of vascular smooth muscle cell phenotype switching in arteriogenesis. Int J Mol Sci. 2021;22:10585.
Miano JM, Fisher EA, Majesky MW. Fate and state of vascular smooth muscle cells in atherosclerosis. Circulation. 2021;143:2110–6.
Ebenhoch R, Akhdar A, Reboll MR, Korf-Klingebiel M, Gupta P, Armstrong J, et al. Crystal structure and receptor-interacting residues of MYDGF-a protein mediating ischemic tissue repair. Nat Commun. 2019;10:5379.
Cully M. Cardiovascular disease: MYDGF promotes heart repair after myocardial infarction. Nat Rev Drug Discov. 2015;14:164–5.
Wang Y, Li Y, Feng J, Liu W, Li Y, Liu J, et al. Mydgf promotes cardiomyocyte proliferation and neonatal heart regeneration. Theranostics. 2020;10:9100–12.
Korf-Klingebiel M, Reboll MR, Polten F, Weber N, Jäckle F, Wu X, et al. Myeloid-derived growth factor protects against pressure overload-induced heart failure by preserving sarco/endoplasmic reticulum Ca2+-ATPase expression in cardiomyocytes. Circulation. 2021;144:1227–40.
He M, Li Y, Wang L, Guo B, Mei W, Zhu B, et al. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease. Diabetologia. 2020;63:1916–31.
Li DJ, Fu H, Tong J, Li YH, Qu LF, Wang P, et al. Cholinergic anti-inflammatory pathway inhibits neointimal hyperplasia by suppressing inflammation and oxidative stress. Redox Biol. 2018;15:22–33.
Meng B, Li Y, Ding Y, Xu X, Wang L, Guo B, et al. Myeloid-derived growth factor inhibits inflammation and alleviates endothelial injury and atherosclerosis in mice. Sci Adv. 2021;7:eabe6903.
Xu X, Li Y, Shi L, He K, Sun Y, Ding Y, et al. Myeloid-derived growth factor (MYDGF) protects bone mass through inhibiting osteoclastogenesis and promoting osteoblast differentiation. EMBO Rep. 2022;23:e53509.
Tulis DA. Rat carotid artery balloon injury model. Methods Mol Med. 2007;139:1–30.
Zhang JR, Lu QB, Feng WB, Wang HP, Tang ZH, Cheng H, et al. Nesfatin-1 promotes VSMC migration and neointimal hyperplasia by upregulating matrix metalloproteinases and downregulating PPARγ. Biomed Pharmacother. 2018;102:711–7.
Fan Y, Zhang J, Chen CY, Xiao YB, Asico LD, Jose PA, et al. Macrophage migration inhibitory factor triggers vascular smooth muscle cell dedifferentiation by a p68-serum response factor axis. Cardiovasc Res. 2017;113:519–30.
Charles R, Bourmoum M, Claing A. ARF GTPases control phenotypic switching of vascular smooth muscle cells through the regulation of actin function and actin dependent gene expression. Cell Signal. 2018;46:64–75.
Medlin MD, Staus DP, Dubash AD, Taylor JM, Mack CP. Sphingosine 1-phosphate receptor 2 signals through leukemia-associated RhoGEF (LARG), to promote smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol. 2010;30:1779–86.
Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem. 2007;282:37244–55.
Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem. 2001;276:341–7.
Wilson S, Mone P, Kansakar U, Jankauskas SS, Donkor K, Adebayo A, et al. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21:23.
Shi J, Yang Y, Cheng A, Xu G, He F. Metabolism of vascular smooth muscle cells in vascular diseases. Am J Physiol Heart Circ Physiol. 2020;319:H613–31.
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118:692–702.
Yap C, Mieremet A, de Vries CJM, Micha D, de Waard V. Six shades of vascular smooth muscle cells illuminated by KLF4 (Krüppel-Like Factor 4). Arterioscler Thromb Vasc Biol. 2021;41:2693–707.
Badran A, Nasser SA, Mesmar J, El-Yazbi AF, Bitto A, Fardoun MM, et al. reactive oxygen species: modulators of phenotypic switch of vascular smooth muscle cells. Int J Mol Sci. 2020;21:E8764.
Zhang F, Guo X, Xia Y, Mao L. An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis. Cell Mol Life Sci. 2021;79:6.
Minai-Tehrani A, Chang SH, Kwon JT, Hwang SK, Kim JE, Shin JY, et al. Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras (LA1) mice. Cell Oncol. 2013;36:15–26.
Yan C. Cyclic nucleotide phosphodiesterase 1 and vascular aging. Clin Sci. 2015;129:1077–81.
Ullrich H, Olschewski M, Münzel T, Gori T. Coronary in-stent restenosis: predictors and treatment. Dtsch Arztebl Int. 2021;118:637–44.
Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Weilenmann D, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020;396:1504–10.
Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020;13:1391–402.
McDonald AI, Iruela-Arispe ML. Healing arterial ulcers: endothelial lining regeneration upon vascular denudation injury. Vasc Pharmacol. 2015;72:9–15.
Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol. 2010;11:353–65.
Xia XD, Zhou Z, Yu XH, Zheng XL, Tang CK. Myocardin: a novel player in atherosclerosis. Atherosclerosis. 2017;257:266–78.
Cenik BK, Liu N, Chen B, Bezprozvannaya S, Olson EN, Bassel-Duby R. Myocardin-related transcription factors are required for skeletal muscle development. Development. 2016;143:2853–61.
Frismantiene A, Philippova M, Erne P, Resink TJ. Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. Cell Signal. 2018;52:48–64.
Zhu B, Rippe C, Holmberg J, Zeng S, Perisic L, Albinsson S, et al. Nexilin/NEXN controls actin polymerization in smooth muscle and is regulated by myocardin family coactivators and YAP. Sci Rep. 2018;8:13025.
Hu J, Li Y, Wei Z, Chen H, Sun X, Zhou Q, et al. A reduction in the vascular smooth muscle cell focal adhesion component syndecan-4 is associated with abdominal aortic aneurysm formation. Clin Transl Med. 2021;11:e605.
Liao KA, Rangarajan KV, Bai X, Taylor JM, Mack CP. The actin depolymerizing factor destrin serves as a negative feedback inhibitor of smooth muscle cell differentiation. Am J Physiol Heart Circ Physiol. 2021;321:H893–904.
Chen H, Wang J, Zhang C, Ding P, Tian S, Chen J, et al. Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases. Biomed Pharmacother. 2022;153:113341.
Mousseau Y, Mollard S, Richard L, Nizou A, Faucher-Durand K, Cook-Moreau J, et al. Fingolimod inhibits PDGF-B-induced migration of vascular smooth muscle cell by down-regulating the S1PR1/S1PR3 pathway. Biochimie. 2012;94:2523–31.
Wamhoff BR, Lynch KR, Macdonald TL, Owens GK. Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol. 2008;28:1454–61.
Yang Q, Shi W. Rho/ROCK-MYOCD in regulating airway smooth muscle growth and remodeling. Am J Physiol Lung Cell Mol Physiol. 2021;321:L1–5.
Acknowledgements
This work was supported by National Natural Science Foundation of China (82170431, 81870259, 81903608).
Author information
Authors and Affiliations
Contributions
SY designed research; SY, TTZ, JYT, CYM, YC, Yu Zhao, QL, LYJ, Zhengkai Wang, Zhiqi Wang, WYJ, MF, SFC, Xue Li and JR and performed research; SY analyzed data; SY wrote the paper. Yan Zhang, HWL, Yixiu Zhao helped perform the analysis with constructive discussions. Yan Zhang and Xue Liu helped polish the article.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yang, S., Li, Hw., Tian, Jy. et al. Myeloid-derived growth factor suppresses VSMC dedifferentiation and attenuates postinjury neointimal formation in rats by activating S1PR2 and its downstream signaling. Acta Pharmacol Sin 45, 98–111 (2024). https://doi.org/10.1038/s41401-023-01155-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41401-023-01155-x